prod:prod_dcx-login
Xpert® SA Nasal Complete
Pre-surgical testing of S. aureus and MRSA in about 65 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXSACOMP-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
Staphylococcus aureus infections are an increasingly serious public health issue.
Colonized patients at risk for serious complications include surgical, trauma, burn and dialysis patients:
Colonized patients at risk for serious complications include surgical, trauma, burn and dialysis patients:
- S. aureus colonized patients are up to 9 times more likely to develop surgical site infections than non-carriers1
- S. aureus is the major cause of access infections and bacteremia in dialysis patients2
- Carriage is the major risk factor for infection with S. aureus in dialysis patients4
- Up to 93% of nosocomial S. aureus infections are caused by a patient's own flora3,4
- SA and MRSA infections are associated with increases in length of hospital stay, costs, morbidity, and mortality6,7,11
- Nasal carriage of S. aureus and self-infection of wounds in ICU/Burn patients is well documented9,10
(1) Kluytmans J, et al. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997 Jul;10(3):505-20.
(2) Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. ASAIO J. 2000 Nov-Dec;46(6):S13-7.
(3) Critchley IA. Eradication of MRSA nasal colonization as a strategy for infection prevention. Drug Discov. Today. 2006;3(2):189-95.
(4) Yu VL, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med. 1986 Jul 10;315(2):91-6.
(5) Murphy D, et al. Dispelling the Myths: The True Cost of Healthcare-Associated Infections. An APIC Briefing. 2007 Feb. Accessed May 2020. http://www.thainapci.org/download-guideline-6.pdf/
(6) Engemann JJ, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003 Mar 1;36(5):592-8. Epub 2003 Feb 7.
(7) Anderson, DJ. Clinical and Financial Outcomes Due to Methicillin Resistant Staphylococcus aureus Surgical Site Infection: A Multi-Center Matched Outcomes Study. PLOS One. 2009 Dec 15. Accessed May 2020. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008305
(8) Bode LG, et al. Preventing Surgical-Site Infections in Nasal Carriers of Staphylococcus aureus. N Engl J Med. 2010 Jan 7;362:9-17.
(9) Mackie DP, et al. Reduction in Staphylococcus aureus wound colonization using nasal mupirocin and selective decontamination of the digestive tract in extensive burns. Burns. 1994;20 Suppl 1:S14-7; discussion S17-8.
(10) Kooistra-Smid M, et al. Molecular epidemiology of Staphylococcus aureus colonization in a burn center. Burns. 2004 Feb;30(1):27-33.
(11) Noskin GA, et al. The Burden of Staphylococcus aureus Infections on Hospitals in the United States. Arch Intern Med.2005;165(15):1756–1761.
(2) Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. ASAIO J. 2000 Nov-Dec;46(6):S13-7.
(3) Critchley IA. Eradication of MRSA nasal colonization as a strategy for infection prevention. Drug Discov. Today. 2006;3(2):189-95.
(4) Yu VL, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med. 1986 Jul 10;315(2):91-6.
(5) Murphy D, et al. Dispelling the Myths: The True Cost of Healthcare-Associated Infections. An APIC Briefing. 2007 Feb. Accessed May 2020. http://www.thainapci.org/download-guideline-6.pdf/
(6) Engemann JJ, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003 Mar 1;36(5):592-8. Epub 2003 Feb 7.
(7) Anderson, DJ. Clinical and Financial Outcomes Due to Methicillin Resistant Staphylococcus aureus Surgical Site Infection: A Multi-Center Matched Outcomes Study. PLOS One. 2009 Dec 15. Accessed May 2020. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008305
(8) Bode LG, et al. Preventing Surgical-Site Infections in Nasal Carriers of Staphylococcus aureus. N Engl J Med. 2010 Jan 7;362:9-17.
(9) Mackie DP, et al. Reduction in Staphylococcus aureus wound colonization using nasal mupirocin and selective decontamination of the digestive tract in extensive burns. Burns. 1994;20 Suppl 1:S14-7; discussion S17-8.
(10) Kooistra-Smid M, et al. Molecular epidemiology of Staphylococcus aureus colonization in a burn center. Burns. 2004 Feb;30(1):27-33.
(11) Noskin GA, et al. The Burden of Staphylococcus aureus Infections on Hospitals in the United States. Arch Intern Med.2005;165(15):1756–1761.
The Solution
Rapid and accurate detection of colonization facilitates targeted infection control practices:
- Optimize pre-admission workflow and counseling
- Enables measures to reduce endogenous infection risk, including decolonization
- Supports measures to reduced exogenous infection risk, including barrier/contact precautions
- Aligns with infection control strategies as outlined by SCIP and SHEA/IDSA
The Impact
Surgical Site Infections (SSIs) due to SA & MRSA significantly increase risk of death, costs and hospitalization as compared to surgeries without SSIs.6,7
Rapid detection and implementation of targeted control measures improves your bottom line by reducing adverse medical care events. Hospitals absorb most of the costs for adverse medical care events.(6) Engemann JJ, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003 Mar 1;36(5):592-8. Epub 2003 Feb 7.
(7) Anderson, DJ. Clinical and Financial Outcomes Due to Methicillin Resistant Staphylococcus aureus Surgical Site Infection: A Multi-Center Matched Outcomes Study. PLOS One. 2009 Dec 15. Accessed May 2020. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008305
(7) Anderson, DJ. Clinical and Financial Outcomes Due to Methicillin Resistant Staphylococcus aureus Surgical Site Infection: A Multi-Center Matched Outcomes Study. PLOS One. 2009 Dec 15. Accessed May 2020. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008305
Related Products
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections In About One Hour
Xpert C. difficile/Epi
Detection of Clostridium difficileinfection with an independent call-out of the 027 strain in around 45 minutes
Xpert C. difficile
Detection of Clostridium difficile in 40 minutes*
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 50 minutes
Xpert vanA
Rapid VRE screening for active outbreak prevention and control in around 48 minutes
Xpert Norovirus
Fast and accurate identification of Norovirus GI & GII in as little as one hour* *With early assay termination for positive results. Reporting negative results in 90 minutes.
Xpert MRSA/SA Blood Culture
Accurate Detection of MRSA and SA in Positive Blood Culture Specimens in About an Hour
Xpert MRSA NxG
Active MRSA surveillance testing in around 70 minutes
Xpert vanA/vanB
Rapid VRE screening for active outbreak prevention and control in around 48 minutes